Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|July 2, 2004
- Pharmaceutical Technology-07-02-2004
- Volume 28
- Issue 7
Investors Shy Away from Pharmaceutical Chemicals
Author(s)Jim Miller
Despite investors' strong interest in the chemical industry overall, pharmaceutical chemical businesses have not experienced much attention from investors thus far.
Articles in this issue
over 22 years ago
3M Drug Delivery Systemsover 22 years ago
AccuRateover 22 years ago
July 2004over 22 years ago
In the Spotlight-July 2004over 22 years ago
A Stability Program for the Distribution of Drug Productsover 22 years ago
Politics Versus Science in Biomedical Research and DevelopmentRelated to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.